Green TR Cells  by Feuerer, Markus et al.
Immunity, Vol. 22, 271–274, March, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.immuni.2005.03.002
PreviewsGreen TR Cells
Identification of the transcription factor Foxp3 as a
“master regulator” of regulatory T (TR) cells was a
major discovery. A new study by Fontenot et al.
(2005), reported in this issue of Immunity, provides
novel insights into TR cell biology by tracking their
behavior in mice expressing a GFP-Foxp3 fusion-pro-
tein reporter.
All higher organisms harbor autoreactive T cells, which
somehow survived central tolerance induction (i.e.,
negative selection during thymocyte differentiation)
and have the potential of inducing organ-specific auto-
immune disease (Ohashi, 2003). Therefore, in order for
self-tolerance to be maintained, several peripheral tol-
erance mechanisms have evolved, including deletion,
anergy, and active control of autoreactive T cells. (Van
Parijs and Abbas, 1998).
Since the middle of the 1990s, a subset of T cells
expressing the high affinity IL-2 receptor alpha chain
(CD25) has emerged as a focus for immunologists inter-
ested in immunoregulation (Sakaguchi et al., 1995).
CD4+CD25+ TR cells are now known to play a central
role in the maintenance of immunological homeosta-
sis and self-tolerance in a number of autoimmunity, al-
lergy, and infection models (for review see Sakaguchi
[2004] and Shevach [2002]).
Nonetheless, a means of definitively identifying TR cells
has been elusive. CD25 expression is most commonly
employed as a marker, and glucocorticoid-induced TNF
receptor-related gene (GITR), cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4), neuropilin-1, or the
integrin αE (CD103) have also been used, but none of
these molecules is really restricted to TR cells. They are
also expressed on T effector cell precursors upon acti-
vation, with the exception of neuropilin-1 and CD103,
although the latter molecule can be induced in the
presence of TGF-β. Recently, Foxp3, a member of the
well-known and diverse forkhead transcription factor
family, was identified as a master switch in TR cell dif-
ferentiation and function (Hori et al., 2003; Fontenot et
al., 2003; Khattri et al., 2003). Because Foxp3 is not
upregulated in recently activated CD4+CD25− T cells, it
seemed to be an excellent candidate for a specific
marker of TR cells.
By using mice harboring a GFP-Foxp3 fusion-protein
reporter knockin allele, Fontenot and colleagues have
now explored the role of Foxp3 in the hematopoietic
system; in particular, the relationship between Foxp3
expression, cell-surface display of CD25, and TR activ-
ity (Fontenot et al., 2005). In control studies, they first
established the functional integrity of Foxp3 in reporter
mice by demonstrating that TR cells isolated from them
had normal suppressive activity. Expression of the tran-
scription factor fusion protein in the peripheral immune
system was largely restricted to a small population ofTCRβ+CD4+ T cells (which constituted 97% of the
Foxp3gfp+ cells). Tiny populations of CD8+ T cells as
well as CD4/CD8 double-positive and double-negative
T cells that made Foxp3gfp could also be discerned.
Based on expression of Foxp3gfp and CD25, CD4+ T
cells could be divided into four subpopulations. Per-
haps surprisingly to some, Foxp3 expression and TR
cell function were not well correlated with display of
CD25. Notably, less than 50% of the Foxp3gfp+ lympho-
cytes isolated from the lungs exhibited high levels of
CD25. It seems that CD25highFoxp3gfp+ and CD25lo/neg
Foxp3gfp+ CD4+ T cells represent the pool of regulatory
T cells, whereas the CD25highFoxp3gfp− population has
an activated/effector phenotype with no regulatory po-
tential (at least under the conditions analyzed in this
study).
Compatible with a breakdown in peripheral self-toler-
ance, mice with a deficiency in Foxp3 show a rapid,
fatal lymphoproliferative autoimmune syndrome at 3–4
weeks of age. Given that Foxp3-deficient mice display
a much more severe autoimmune phenotype than do
mice depleted of CD25+ cells, there has been specula-
tion that Foxp3 might have an additional as-yet-unchar-
acterized role. However, Fontenot et al. (2005) made
several arguments against this notion. First, this tran-
scription factor was not expressed in any non-T cell
populations, as was clearly evident from examining
expression of the Foxp3-GFP-reporter in lymphocyte-
deficient RAGo/o mice. Second, a T cell-specific abla-
tion of Foxp3 was sufficient to induce the full lympho-
proliferative autoimmune syndrome observed in standard
Foxp3-deficient mice. Third, a lack of Foxp3 did not
influence the effector responses by T cells from Foxp3/
RAG double-deficient T cell receptor transgenic mice.
This finding argues against any cell-intrinsic function
for Foxp3 in effector T cells, suggesting an exclusive
role in regulatory T cells.
Most striking, and in contrast to previous assump-
tions (Stock et al., 2004), “adaptive” Foxp3-expressing
TR cells were not induced (as a form of feedback regu-
lation) during the course of an acute immune response.
There was no induction of this transcription factor after
7 days of in vitro culture in the presence of antigen and
no de novo generation of Foxp3gfp+ cells in the course
of an acute pathogen-driven immune response. Whether
the system used by Fontenot et al. (2005) was sufficient
to rule out any extrathymic induction of TR cells remains
in question, particularly in light of recent reports of the
conversion of naive T cells into TR cells in vivo (Liang
et al., 2005; Apostolou and von Boehmer, 2004).
In another interesting, though still somewhat prelimi-
nary, set of experiments, the important question of TR
cell differentiation in the thymus was addressed. Ex-
pression of Foxp3 was largely restricted to CD4 single-
positive thymocytes; however, minor populations of
CD8 single-positive, double-positive, and double-nega-
tive thymocytes were also detectable. Foxp3 expres-
sion was strictly dependent on TCR/MHC molecule in-
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272teraction. Surprisingly, and consistent with the data M
afrom the periphery, a fraction of the Foxp3gfp+ cells rep-
resented CD8+ thymocytes dependent on expression of S
JMHC class I molecules.
Overall, this study has established the validity of D
BFoxp3 as a specific marker for regulatory T cells and
has reported a novel mouse line of tremendous poten- H
Otial value in studies on immunoregulation. It has also
raised some intriguing questions. Can the newly dis- B
covered CD8+Foxp3gfp+ T cells exert regulatory func-
tion comparable with that of CD4+CD25+ TR cells? If so,
Sin what context(s) do they emerge as important control
elements? Foxp3gfp+ TR cells isolated from diverse A
sites showed some striking phenotypic differences; 1
for example, peripheral organs were enriched in the
F
CD25lo/negFoxp3gfp+ population, which had an activated n
phenotype and included proliferating cells. Might these F
cells be the key to self-tolerance within tissues? Unlike A
CD4+CD25+ TR cells, other immune cells with regulatory H
potential, including NKT cells and Tr1 cells, express no 1
or low levels of Foxp3; thus, it is unlikely that this tran- K
Iscription factor and the gene-expression program it
specifies is the only means of establishing tolerance L
Mdominantly. What is the master regulator of these cell-
Otypes and when do they come into play?
The powerful in vivo model introduced by Fontenot S
et al. (2005) opens the door for new insights into TR cell S
(biology. There is sure to be an onslaught of studies on
antigen-specific systems, as well as adaptations to a S
diversity of pathological situations, including autoim- S
Umunity, chronic infection, transplantation, and tumori-
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